Loading
Life sciences · Journal article
Pharmaceutics · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by progression, metastasis, and treatment resistance. Although options include immune checkpoint inhibitors, PARP inhibitors for selected patients, and antibody–drug conjugates, the absence of a single widely applicable molecular target and tumor heterogeneity remain challenges. Increased glycolytic activity in some TNBC tumors provides a rationale for metabolic intervention, although glucose dependence varies among tumors. Glucose oxidase (GOx) catalyzes the oxidation of accessible glucose in the presence of molecular oxygen, generating hydrogen peroxide (H2O2) and gluconic acid. Depending on nanoplatform design and enzyme localization, glucose depletion may occur in the extracellular tumor microenvironment or intracellular compartments following cellular uptake and enzyme release. However, free GOx is limited by poor physiological stability, rapid inactivation, oxygen dependence, inadequate tumor accumulation, and systemic toxicity. Nanotechnology offers strategies to improve enzyme stability and tumor-selective delivery while integrating complementary therapies. Preclinical studies have investigated GOx-loaded nanoplatforms combining metabolic starvation with chemotherapy, chemodynamic therapy, ferroptosis induction, photodynamic and photothermal therapy, radiotherapy, and immunotherapy. Although these platforms demonstrate promising antitumor activity in experimental models, efficacy and proposed mechanisms vary across formulations and models. Pharmacological synergy should be claimed only when supported by quantitative analyses. Tumor heterogeneity, oxygen dependence, toxicity, manufacturing complexity, and regulatory challenges remain major translational barriers. Overall, current findings provide a strong preclinical rationale for further investigation of GOx-loaded nanotherapeutics, but do not establish clinical efficacy in human patients or permit predictions regarding future clinical adoption for TNBC.